Mn Services Vermogensbeheer B.V. Lowers Stock Position in AbbVie Inc. (NYSE:ABBV)

Mn Services Vermogensbeheer B.V. lowered its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 6.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 649,104 shares of the company's stock after selling 48,300 shares during the quarter. AbbVie makes up about 1.1% of Mn Services Vermogensbeheer B.V.'s investment portfolio, making the stock its 17th largest holding. Mn Services Vermogensbeheer B.V.'s holdings in AbbVie were worth $136,000,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Blue Bell Private Wealth Management LLC grew its stake in AbbVie by 30.4% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 223 shares of the company's stock worth $40,000 after buying an additional 52 shares during the period. Steel Grove Capital Advisors LLC lifted its holdings in shares of AbbVie by 1.7% during the 4th quarter. Steel Grove Capital Advisors LLC now owns 3,110 shares of the company's stock valued at $553,000 after acquiring an additional 52 shares in the last quarter. Peninsula Wealth LLC boosted its position in AbbVie by 4.1% during the 4th quarter. Peninsula Wealth LLC now owns 1,360 shares of the company's stock worth $242,000 after purchasing an additional 54 shares during the period. Physicians Financial Services Inc. raised its position in AbbVie by 0.5% in the fourth quarter. Physicians Financial Services Inc. now owns 12,150 shares of the company's stock valued at $2,159,000 after purchasing an additional 55 shares during the period. Finally, Connecticut Wealth Management LLC lifted its stake in shares of AbbVie by 1.6% during the fourth quarter. Connecticut Wealth Management LLC now owns 3,711 shares of the company's stock worth $660,000 after purchasing an additional 57 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Jeffrey Ryan Stewart sold 58,832 shares of AbbVie stock in a transaction on Monday, March 31st. The shares were sold at an average price of $210.08, for a total value of $12,359,426.56. Following the completion of the sale, the executive vice president now directly owns 53,234 shares of the company's stock, valued at approximately $11,183,398.72. The trade was a 52.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.25% of the company's stock.

AbbVie Price Performance

Shares of AbbVie stock traded down $0.31 during trading on Monday, reaching $190.77. 1,048,347 shares of the company's stock were exchanged, compared to its average volume of 6,230,984. The firm's 50-day moving average price is $184.21 and its 200 day moving average price is $187.55. The company has a market cap of $336.98 billion, a P/E ratio of 79.38, a PEG ratio of 1.62 and a beta of 0.50. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66. AbbVie Inc. has a 1-year low of $163.52 and a 1-year high of $218.66.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. The company had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The firm's quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the company posted $2.31 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ABBV. Citigroup lifted their price objective on shares of AbbVie to $205.00 and gave the company a "hold" rating in a research note on Wednesday, June 11th. Wells Fargo & Company increased their target price on shares of AbbVie from $210.00 to $240.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Erste Group Bank upgraded shares of AbbVie to a "strong-buy" rating in a research note on Monday, March 17th. Finally, Bank of America increased their target price on shares of AbbVie to $204.00 and gave the company a "hold" rating in a research report on Monday, June 9th. Eight research analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $211.29.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.